---
document_datetime: 2025-12-17 23:29:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/anzupgo.html
document_name: anzupgo.html
version: success
processing_time: 0.1205753
conversion_datetime: 2025-12-23 23:57:58.264763
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Anzupgo

[RSS](/en/individual-human-medicine.xml/246160)

##### Authorised

This medicine is authorised for use in the European Union

delgocitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Anzupgo](#news-on)
- [More information on Anzupgo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Anzupgo is used to treat moderate to severe chronic hand eczema (a long-term condition where the skin of the hands is itchy, red and dry) in adults who cannot use corticosteroids applied to the skin or in whom such corticosteroids do not work well enough.

Anzupgo contains the active substance delgocitinib.

Expand section

Collapse section

## How is Anzupgo used?

Anzupgo can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the diagnosis and treatment of chronic hand eczema.

Anzupgo is available as a cream, that is applied as a thin layer to affected skin of the hands and wrists twice a day. The cream should be applied at regular intervals and treatment should be continued until symptoms improve or disappear, after which it can be stopped. If symptoms recur, treatment can be re-started as needed. If no improvement is seen after 12 weeks of continuous treatment, treatment should be stopped.

For more information about using Anzupgo, see the package leaflet or contact your doctor or pharmacist.

## How does Anzupgo work?

The active substance in Anzupgo, delgocitinib, works by blocking the action of enzymes (proteins) known as Janus kinases. These enzymes play an important role in the process of inflammation that occurs in chronic hand eczema. Delgocitinib helps reduce the inflammation and other symptoms of the condition.

## What benefits of Anzupgo have been shown in studies?

Anzupgo was more effective than a placebo (dummy) cream at reducing the extent and severity of symptoms in two main studies involving 960 adults with moderate to severe chronic hand eczema. In both studies, the main measure of effectiveness was the proportion of patients who achieved a score of 0 (clear) or 1 (almost clear) on a 5-point scale for chronic hand eczema (the IGA-CHE scale), with an improvement of at least 2 points after 16 weeks of treatment.

The results showed that most, or all, of the chronic hand eczema had cleared up in around 20% of patients treated with Anzupgo in the first study compared with around 10% of patients using placebo. In the second study, these figures were around 29% for patients treated with Anzupgo and around 7% for patients using placebo.

## What are the risks associated with Anzupgo?

For the full list of side effects and restrictions with Anzupgo, see the package leaflet.

The most common side effects with Anzupgo (which may affect 1 in 100 people) include application site reactions such as itching, redness, pain and a burning or prickling sensation.

## Why is Anzupgo authorised in the EU?

Anzupgo reduces the extent and severity of chronic hand eczema in adults with moderate to severe disease who cannot use corticosteroids that are applied to the skin or in whom such corticosteroids do not work well enough. At the time of approval of Anzupgo, treatment options for these patients were very limited.

Regarding safety, Anzupgo's side effects are generally mild and manageable. The European Medicines Agency therefore decided that Anzupgo's benefits are greater than its risks and it can be authorised in the EU.

## What measures are being taken to ensure the safe and effective use of Anzupgo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Anzupgo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Anzupgo are continuously monitored. Suspected side effects reported with Anzupgo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Anzupgo

Anzupgo received a marketing authorisation valid throughout the EU on 19 September 2024.

Anzupgo : EPAR - Medicine overview

Reference Number: EMA/355342/2024

English (EN) (115.37 KB - PDF)

**First published:** 24/09/2024

[View](/en/documents/overview/anzupgo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-78)

български (BG) (138.08 KB - PDF)

**First published:**

24/09/2024

[View](/bg/documents/overview/anzupgo-epar-medicine-overview_bg.pdf)

español (ES) (114.49 KB - PDF)

**First published:**

24/09/2024

[View](/es/documents/overview/anzupgo-epar-medicine-overview_es.pdf)

čeština (CS) (135.39 KB - PDF)

**First published:**

24/09/2024

[View](/cs/documents/overview/anzupgo-epar-medicine-overview_cs.pdf)

dansk (DA) (123.57 KB - PDF)

**First published:**

24/09/2024

[View](/da/documents/overview/anzupgo-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.8 KB - PDF)

**First published:**

24/09/2024

[View](/de/documents/overview/anzupgo-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.95 KB - PDF)

**First published:**

24/09/2024

[View](/et/documents/overview/anzupgo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (138 KB - PDF)

**First published:**

24/09/2024

[View](/el/documents/overview/anzupgo-epar-medicine-overview_el.pdf)

français (FR) (115.53 KB - PDF)

**First published:**

24/09/2024

[View](/fr/documents/overview/anzupgo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134.63 KB - PDF)

**First published:**

24/09/2024

[View](/hr/documents/overview/anzupgo-epar-medicine-overview_hr.pdf)

italiano (IT) (113.67 KB - PDF)

**First published:**

24/09/2024

[View](/it/documents/overview/anzupgo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (154.76 KB - PDF)

**First published:**

24/09/2024

[View](/lv/documents/overview/anzupgo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (135.09 KB - PDF)

**First published:**

24/09/2024

[View](/lt/documents/overview/anzupgo-epar-medicine-overview_lt.pdf)

magyar (HU) (133.51 KB - PDF)

**First published:**

24/09/2024

[View](/hu/documents/overview/anzupgo-epar-medicine-overview_hu.pdf)

Malti (MT) (146.5 KB - PDF)

**First published:**

24/09/2024

[View](/mt/documents/overview/anzupgo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (114.5 KB - PDF)

**First published:**

24/09/2024

[View](/nl/documents/overview/anzupgo-epar-medicine-overview_nl.pdf)

polski (PL) (136.45 KB - PDF)

**First published:**

24/09/2024

[View](/pl/documents/overview/anzupgo-epar-medicine-overview_pl.pdf)

português (PT) (115.86 KB - PDF)

**First published:**

24/09/2024

[View](/pt/documents/overview/anzupgo-epar-medicine-overview_pt.pdf)

română (RO) (134.16 KB - PDF)

**First published:**

24/09/2024

[View](/ro/documents/overview/anzupgo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (135.97 KB - PDF)

**First published:**

24/09/2024

[View](/sk/documents/overview/anzupgo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (134.64 KB - PDF)

**First published:**

24/09/2024

[View](/sl/documents/overview/anzupgo-epar-medicine-overview_sl.pdf)

Suomi (FI) (112.99 KB - PDF)

**First published:**

24/09/2024

[View](/fi/documents/overview/anzupgo-epar-medicine-overview_fi.pdf)

svenska (SV) (114.13 KB - PDF)

**First published:**

24/09/2024

[View](/sv/documents/overview/anzupgo-epar-medicine-overview_sv.pdf)

Anzupgo : EPAR - Risk management plan

English (EN) (792.22 KB - PDF)

**First published:** 24/09/2024

[View](/en/documents/rmp/anzupgo-epar-risk-management-plan_en.pdf)

## Product information

Anzupgo : EPAR - Product information

English (EN) (423.95 KB - PDF)

**First published:** 24/09/2024

**Last updated:** 08/12/2025

[View](/en/documents/product-information/anzupgo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-998)

български (BG) (470.21 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/bg/documents/product-information/anzupgo-epar-product-information_bg.pdf)

español (ES) (431.82 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/es/documents/product-information/anzupgo-epar-product-information_es.pdf)

čeština (CS) (459.99 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/cs/documents/product-information/anzupgo-epar-product-information_cs.pdf)

dansk (DA) (425.59 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/da/documents/product-information/anzupgo-epar-product-information_da.pdf)

Deutsch (DE) (447.18 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/de/documents/product-information/anzupgo-epar-product-information_de.pdf)

eesti keel (ET) (433.65 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/et/documents/product-information/anzupgo-epar-product-information_et.pdf)

ελληνικά (EL) (502.57 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/el/documents/product-information/anzupgo-epar-product-information_el.pdf)

français (FR) (438.34 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/fr/documents/product-information/anzupgo-epar-product-information_fr.pdf)

hrvatski (HR) (463.13 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/hr/documents/product-information/anzupgo-epar-product-information_hr.pdf)

íslenska (IS) (446.65 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/is/documents/product-information/anzupgo-epar-product-information_is.pdf)

italiano (IT) (422.45 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/it/documents/product-information/anzupgo-epar-product-information_it.pdf)

latviešu valoda (LV) (448.4 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/lv/documents/product-information/anzupgo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (470.65 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/lt/documents/product-information/anzupgo-epar-product-information_lt.pdf)

magyar (HU) (477.74 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/hu/documents/product-information/anzupgo-epar-product-information_hu.pdf)

Malti (MT) (479.65 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/mt/documents/product-information/anzupgo-epar-product-information_mt.pdf)

Nederlands (NL) (432.71 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/nl/documents/product-information/anzupgo-epar-product-information_nl.pdf)

norsk (NO) (417.75 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/no/documents/product-information/anzupgo-epar-product-information_no.pdf)

polski (PL) (477.15 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/pl/documents/product-information/anzupgo-epar-product-information_pl.pdf)

português (PT) (425.45 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/pt/documents/product-information/anzupgo-epar-product-information_pt.pdf)

română (RO) (496.05 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/ro/documents/product-information/anzupgo-epar-product-information_ro.pdf)

slovenčina (SK) (479.81 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/sk/documents/product-information/anzupgo-epar-product-information_sk.pdf)

slovenščina (SL) (475.77 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/sl/documents/product-information/anzupgo-epar-product-information_sl.pdf)

Suomi (FI) (428.73 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/fi/documents/product-information/anzupgo-epar-product-information_fi.pdf)

svenska (SV) (420.61 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

08/12/2025

[View](/sv/documents/product-information/anzupgo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000264200 23/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Anzupgo : EPAR - All authorised presentations

English (EN) (47.31 KB - PDF)

**First published:** 24/09/2024

**Last updated:** 18/06/2025

[View](/en/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-895)

български (BG) (65.23 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/bg/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.98 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/es/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.98 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/cs/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.85 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/da/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.73 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/de/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.99 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/et/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.76 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/el/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_el.pdf)

français (FR) (47.32 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/fr/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.35 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/hr/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.83 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/is/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.76 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/it/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.83 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/lv/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.61 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/lt/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.53 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/hu/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.14 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/mt/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.25 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/nl/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.54 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/no/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.95 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/pl/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_pl.pdf)

português (PT) (45.52 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/pt/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.34 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/ro/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.45 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/sk/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.11 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/sl/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.24 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/fi/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.81 KB - PDF)

**First published:**

24/09/2024

**Last updated:**

18/06/2025

[View](/sv/documents/all-authorised-presentations/anzupgo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Anzupgo Active substance Delgocitinib International non-proprietary name (INN) or common name delgocitinib Therapeutic area (MeSH)

- Dermatitis
- Eczema

Anatomical therapeutic chemical (ATC) code D11AH11

### Pharmacotherapeutic group

Other dermatological preparations

### Therapeutic indication

Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE)

## Authorisation details

EMA product number EMEA/H/C/006109

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

LEO Pharma A/S

Industriparken 55

Opinion adopted 25/07/2024 Marketing authorisation issued 19/09/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Anzupgo : EPAR - Procedural steps taken and scientific information (archive)

English (EN) (143.2 KB - PDF)

**First published:** 09/12/2025

[View](/en/documents/procedural-steps-after/anzupgo-epar-procedural-steps-taken-scientific-information-archive_en.pdf)

Anzupgo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.9 KB - PDF)

**First published:** 18/06/2025

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/anzupgo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Anzupgo-PAM-0000280076 : EPAR - Assessment report - Variation

Reference Number: EMADOC-1700519818-2222735

English (EN) (490.82 KB - PDF)

**First published:** 06/10/2025

[View](/en/documents/variation-report/anzupgo-pam-0000280076-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Anzupgo : EPAR - Public assessment report

Adopted

Reference Number: EMA/372390/2024

English (EN) (7.47 MB - PDF)

**First published:** 24/09/2024

[View](/en/documents/assessment-report/anzupgo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Anzupgo

Adopted

Reference Number: EMA/CHMP/239042/2024

English (EN) (157.54 KB - PDF)

**First published:** 26/07/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-anzupgo_en.pdf)

#### News on Anzupgo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

#### More information on Anzupgo

- [Prospective, observational, non-interventional, multicenter real-world evidence study on effectiveness and safety of treatment of patients with moderate to severe Chronic Hand Eczema with delgocitinib cream (20mg/g) (REACHED) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000731)

**This page was last updated on** 09/12/2025

## Share this page

[Back to top](#main-content)